The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Cash burning £ 3.5 million per years . Cash at bank as of 31 December 2022 £ 1.64 million.
As of now July 2023. I guess they left with one month salary .
Wait to buy around 1p
Just added 69734 in two purchases. Need some liquidity and then no doubt it will move!
Moving
Very clear that the MMs are trying to create some liquidity here
9 trades today (7 buys, 2 sells) suggests yesterday's drop had a partial impact
But until the volume arrives, the MMs may continue fishing for stops by dropping the bid/offer.
Currently 1.6/1.5
If you can sit on your hands this will eventually come good.
Will only take one RNS relating to the completion of the new plant (due by end of July) and/or some some new order/revenue streams (I suspect the MXC RNS from last week will have a knock on effect soon!)
Hold. Or, if you can - buy more at 1.6!
Only my opinion - but I am certain this will come good.
Be fearful when others are greedy, and greedy when others are fearful.
At 1.7p there has to be some long term upside
What an absolutely ridiculous share
Looks like a leak of some sort.
Looks like the initial 2.5/2.4 drop was off the back of a £300 'at best' sell at 1.78 - someone must be absolutely crazy to sell at that
Anyway - looks like the market has then been spooked and now we sit at 2.1/2.0
Frightening levels - a £2m mcap down here at these levels 🤯
Still a hold for me.
At some point, someone has to come sniffing and will just take the company out at a £2m mcap.
You have m
Just watched the bid/offer move on ZERO trades.
Very odd.
Moved from 3.0/2.8 to 2.5/2.4
A ridiculous 20% drop on nothing.
Just emailed investor relations at Graft
Asking when the repeat order of ArtemiC will be RNS'd
So we had two positive RNS in the last week.. looks like we'll have another on Monday...
In August 2022 MXC Pharma placed an order for $1m of ArtemiC (50,000 units) which they in turn sold on to AMC Pharma.
On Friday, MXC announced a 2nd order for the same amount and value, see RNS below.
https://www.lse.co.uk/rns/MXC/amc-places-another-us1m-order-of-artemic8482-6wqp995tp384oes.html
I suspect we will have a follow on RNS from Graft on Monday morning to confirm.
This simply cannot stay at this level for much longer.
Good potential investment but the cash position could be tight. This is the downside risk for me. Looking at the 2022 results and likely cash now suggests there may be an additional funding requirement. Will wait and see.
For anyone that takes any note of RSI... You might be interested to know it's 2.8
Yes... 2.8
Oversold. Buy.
Zak Mir predicted a gap fill back to around 8p when this was 4.5p, clearly he got that wrong, but I simply cannot find enough downside risk here at 2.8p
Another super positive RNS.
Buys around the 2.7p region are going to do very, very well from here.
Today's RNS is an R&D agreement with a supply chain also.
All the hallmarks of a recovery play from here.
Https://youtu.be/E0SgUtSBJRs
Should you wish to receive GPL information direct please send email to graftpolymer@flagstaffcomms.com
If this opens ANYWHERE 3p I suspect the MMs may have their pants pulled down... What a wonderful RNS 🤯
Graft Polymer, (LON:GPL) the specialty chemicals company offering modified polymer solutions for refiners, compounders and processors, is today announcing the completion and commissioning of a bespoke production equipment site in Slovenia which is due around the end of July 2023, doubling the company's production capacity.
The company operates in two dynamic sectors with strong growth prospects - the global polymer market, set to grow from US$590 billion in 2021 to US$947 billion by 2030 with a CAGR of 5.4% over this period (source: Prescient & Strategic Intelligence); and the global drug delivery devices market, set to grow from US$78.09 billion in 2021 to US$124.83 billion by 2029, with a CAGR of 5.6% over the period (source: DataM market research, November 2022).
Solid business model, organic growth..
No idea why it's so cheap but I'm in at 2.7p
Ridiculous price as far as I can tell. Was 10x this price in January with a £25m mcap.
Mcap currently £2.8m
Not a lot of downside risk here.
Dropped 30% off nothing?
Leaky? Fundraise coming?
Looked cheap a few days ago... Now it's sat at a £3m mcap.
Was available on the bid at 2.78 for around 2 hours before close.
Any ideas?
Graft Polymer is pleased to announce its expansion into the cosmetics industry through the receipt of a commercial purchase order to the Group's GraftBio division. The purchase order is from an Irish cosmetics and luxury skin care producer for water-soluble Cannabidiol ("CBD") solution.
Although this is initially a small-scale purchase order, it demonstrates Graft Polymer's capabilities to diversify product lines and pass rigorous cosmetic testing requirements. The cosmetics product will be available for sale widely in the UK, both online and in the luxury department store Harvey Nichols.
built long term foundations during the past year, enabling us to double our production capacity, positioning us to target larger customers in the industry. Our unique and proprietary product offering gives us a competitive edge in the market, and we are confident that we can continue to build on our success in the coming year.
In summary, during the period our Company has strengthened its positioning for future growth and is now in a position to take on larger orders, with higher margins, at a time when demand for polymer solutions is high. We are optimistic about the projected uplift in the polymer market and are confident in our ability to meet the demands of this growing market. With our unique offerings, strong leadership, and key initiatives, we are well-prepared to capitalise on opportunities and achieve continued success in the coming year and beyond
Looks like the overhang was gone , much narrower spread of 5.25p to 5.5p